News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,899 Results
Type
Article (13487)
Company Profile (103)
Press Release (245309)
Section
Business (87826)
Career Advice (460)
Deals (15316)
Drug Delivery (60)
Drug Development (36467)
Employer Resources (49)
FDA (6234)
Job Trends (6179)
News (149739)
Policy (13992)
Tag
Academia (435)
Africa (312)
Alliances (23035)
Alzheimer's disease (322)
Approvals (6215)
Arizona (35)
Artificial intelligence (40)
Asia (19636)
Australia (2532)
Bankruptcy (143)
Best Places to Work (4199)
Biosimilars (31)
Biotechnology (41)
C2C Services and Suppliers (10601)
California (588)
Canada (432)
Cancer (139)
Career advice (402)
Cell therapy (23)
China (66)
Clinical research (30043)
Collaboration (51)
Compensation (24)
Connecticut (24)
COVID-19 (737)
Cystic fibrosis (21)
Data (98)
Diabetes (26)
Diagnostics (1201)
Drug pricing (47)
Earnings (31139)
Employer resources (43)
Europe (38390)
Events (36260)
Executive appointments (79)
FDA (6299)
Florida (73)
Funding (37)
Gene therapy (40)
GLP-1 (259)
Government (1249)
Healthcare (3503)
Hotbed/Location (177915)
Illinois (67)
Indiana (59)
Infectious disease (741)
Inflammatory bowel disease (40)
Interviews (57)
IPO (5781)
IRA (22)
Job creations (2047)
Job search strategy (371)
Kansas (49)
Layoffs (164)
Legal (3398)
Lung cancer (30)
Manufacturing (45)
Maryland (88)
Massachusetts (517)
Medical device (1252)
Medtech (1254)
Mergers & acquisitions (9473)
Metabolic disorders (100)
Minnesota (37)
Neuroscience (374)
New Jersey (243)
New York (165)
NextGen Class of 2024 (1576)
Non-profit (588)
North Carolina (221)
Northern California (262)
Obesity (60)
Ohio (29)
Opinion (106)
Patents (39)
Pennsylvania (185)
People (28225)
Pharmaceutical (59)
Phase I (7820)
Phase II (12700)
Phase III (11410)
Pipeline (48)
Podcasts (35)
Policy (36)
Postmarket research (1398)
Preclinical (3127)
Press Release (25)
Rare diseases (51)
Real estate (2624)
Regulatory (9691)
Research institute (561)
Resumes & cover letters (55)
South America (496)
Southern California (263)
Startups (1623)
Texas (76)
United States (2609)
Vaccines (90)
Washington State (46)
Weight loss (52)
Date
Today (25)
Last 7 days (228)
Last 30 days (726)
Last 365 days (13312)
2024 (9255)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19034)
2019 (14886)
2018 (11713)
2017 (13890)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
258,899 Results for "recce pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
Recce Pharmaceuticals Ltd today announced its primary anti-infective candidate, RECCE ® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agents in Clinical Development and Preclinical Development.
June 20, 2024
·
3 min read
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd. today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “ Copolymer and Method for Treatment of Bacterial Infection , ” for its anti-infectives, with expiry in 2035.
May 8, 2024
·
3 min read
Drug Development
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
Recce Pharmaceuticals Ltd today announced it received Human Research Ethics Committee (HREC) approval to commence a Phase II trial assessing its lead candidate, RECCE® 327 (R327), as a topical, broad-spectrum gel for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
June 25, 2024
·
4 min read
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
Recce Pharmaceuticals Ltd. today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.
May 13, 2024
·
4 min read
Drug Development
Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327
Recce Pharmaceuticals Ltd today announced positive data from a Phase I/II trial for urinary tract infections (UTIs) and urosepsis, demonstrating that its lead candidate, RECCE® 327 (R327), administered intravenously is safe and efficacious against Escherichia coli (E. coli).
July 1, 2024
·
5 min read
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
April 4, 2024
·
4 min read
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
Recce Pharmaceuticals Ltd today announced it has been issued a trademark registration for RECCE ® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.
March 22, 2024
·
3 min read
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
Recce Pharmaceuticals Ltd today announced the successful batch completion under Good Manufacturing Practices (GMP) for its lead candidate, RECCE® 327 (R327), with the patented manufacturing process now producing 5,000 GMP doses of R327 per week.
April 17, 2024
·
4 min read
Drug Development
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion TrialSix additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in this trial
Recce Pharmaceuticals Ltd., the Company developing a new class of synthetic anti-infectives, announced it completed dosing an additional cohort in its Phase I/II UTI/Urosepsis trial, evaluating RECCE® 327 at fast infusion rates.
June 12, 2024
·
3 min read
Drug Development
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
Recce Pharmaceuticals Ltd today announced it completed dosing healthy subjects in the latest cohort of its Phase I/II trial, evaluating its lead candidate, RECCE ® 327 (R327).
March 19, 2024
·
3 min read
1 of 25,890
Next
